A 'missing not at random' (MNAR) and 'missing at random' (MAR) growth model comparison with a buprenorphine/naloxone
Sterling McPherson1, Celestina Barbosa-Leiker, Mary Rose Mamey
1College of Nursing, Washington State University, Spokane, WA, USA; Department of Psychology, Washington State University, Pullman, WA, USA; Program of Excellence in Addictions Research, Washington State University, Spokane, WA, USA; Program for Rural Mental Health and Substance Abuse Treatment, Washington State University, Spokane, WA, USA; Translational Addictions Research Center, Washington State University, Pullman, WA, USA.
Aims:
To compare three missing data strategies: (i) the latent growth model that assumes the data are missing at random (MAR) model; (ii) the Diggle-Kenward missing not at random (MNAR) model, where dropout is a function of previous/concurrent urinalysis (UA) submissions; and (iii) the Wu-Carroll MNAR model where dropout is a function of the growth factors. DESIGN : Secondary data analysis of a National Drug Abuse Treatment Clinical Trials Network trial that examined a 7-day versus 28-day taper (i.e. stepwise decrease in buprenorphine/naloxone) on the likelihood of submitting an opioid-positive UA during treatment.
Setting:
11 out-patient treatment settings in 10 US cities.
Participants:
A total of 516 opioid-dependent participants.
Measurements:
Opioid UAs provided across the 4-week treatment period.
Findings:
The MAR model showed a significant effect (B = -0.45, P < 0.05) of trial arm on the opioid-positive UA slope (i.e. 28-day taper participants were less likely to submit a positive UA over time) with a small effect size (d = 0.20). The MNAR Diggle-Kenward model demonstrated a significant (B = -0.64, P < 0.01) effect of trial arm on the slope with a large effect size (d = 0.82). The MNAR Wu-Carroll model showed a significant (B = -0.41, P < 0.05) effect of trial arm on the UA slope that was relatively small (d = 0.31).
Conclusions:
This performance comparison of three missing data strategies (latent growth model, Diggle-Kenward selection model, Wu-Carrol selection model) on sample data indicates a need for increased use of sensitivity analyses in clinical trial research. Given the potential sensitivity of the trial arm effect to missing data assumptions, it is critical for researchers to consider whether the assumptions associated with each model are defensible.
Related Concept Videos
01:12Analysis of Population Pharmacokinetic Data
01:13Parameters Affecting Nonlinear Elimination: Zero-Order Input, First-Order Absorption and Two-Compartment Model
When a drug is administered through a constant intravenous infusion and eliminated via nonlinear pharmacokinetics, it follows zero-order input. For example, oral drugs undergo first-order absorption upon administration and are eliminated through nonlinear pharmacokinetics.
In the case of subcutaneously administered drugs,...
01:26Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
00:59Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
01:09Pharmacodynamic Models: Additive and Proportional Drug Effect Model
01:20Comparing the Survival Analysis of Two or More Groups